ArticleJournal of molecular histology2025
Chitosan nanoparticles of rutin mitigated histological changes induced in DNCB-induced colitis by enhanced modulation of inflammation and oxidative stress.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Metabolism-Guided Framework for Selecting Structural Modification or Nano-Delivery Strategies for Oral Rutin.International journal of molecular sciences · 2026Review
- Mucuna pruriens extract as prebiotic and Lactobacillus rhamnosus as probiotic intervention mitigated histological changes in DNCB-induced colitis via GLP-1/Nrf2/NF-κB axis regulation.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory illness of the colon involving increased production of reactive oxygen species (ROS) and involvement of inflammatory cytokinins. The present study aimed to alleviate colitis condition in rats by rutin-loaded chitosan nanoparticles for improving rutin's release profile, solubility, as well as targetability of inflammatory cells in the 2,4-Dinitrochlorobenzene (DNCB)-induced colitis model. This formulation contains chitosan polymer and an ionic crosslinking technique to create polymeric nanoparticles of rutin. The rats were grouped into five groups, with six in each group. The first group (normal control) consisted of rats fed a regular diet and water for 28 days. The second to fifth group of rats received DNCB (20 g/l 300 µl on nap every day for 14 days). Additionally, for 28 days, rutin (57 mg/kg/po/day) and chitosan-rutin nanoparticle (CRNPs) treatment (57 mg/kg/po.), respectively, in third and fourth-group rats, whereas standard medication sulfasalazine (100 mg/kg/po/day) for fifth group rats. DNCB administered in animals showed elevated ROS, Interlukin-6 (IL-6), and Tumor necrosis factor-α (TNF-α) levels compared to normal control. CRNPs showed a significant decrease in these parameters compared to the DNCB group. The protective effect of CRNPs against DNCB-induced inflammation was supported by histological assessment, where it prevented crypt destruction and immune cell infiltration. In conclusion, repeated administration of DNCB induces inflammation in the colon and bloody stool in rats. The current work was the first to show that CRNPs successfully reduced DNCB-induced IBD, possibly via lowering the level of oxidative stress (ROS) and proinflammatory cytokines (IL-6, TNF-α).
Indexed as
Identifiers
40542885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.